Please assess the completion status of the following clinical trial:

Trial Title: Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal women with menstrual cycles that occur approximately every 20-40 days.~2. T1DM (as defined by the American Diabetes Association criteria or judgment of a physician) for at least 2 years prior to the enrollment in the study~3. Age ≥18 y.o. and ≤55 y.o.~4. Use of an insulin pump to treat their diabetes for at least 6 months.~5. Has an identified healthcare provider who can provide advice about diabetes care.~6. Actively using a current insulin pump with pre-defined parameters for glucose goal, carbohydrate ratio, and insulin sensitivity factor.~7. Willingness to do additional fingersticks when requested such as when CGM alarms at low or high end (\<70 mg/dl or \>300 mg/dl),~8. Willingness to come to Center for Diabetes Technology for study visits.~9. Willingness to avoid consumption of acetaminophen-containing products for the duration of the study.~10. Demonstration of proper mental status and cognition for completion of the study.~11. Hemoglobin A1c 5-10%~Exclusion Criteria:~1. Pregnant or intending to get pregnant during study~2. Active enrollment in another clinical trial~3. Medical requirement for acetaminophen-containing products during the study period for more than 1 week~4. Use of medication or intervention that significantly alters the menstrual cycle such as oral contraceptives, depoprovera, or intrauterine device (IUD).~5. Medical condition that would make operating a CGM or insulin pump difficult (e.g. blindness, severe arthritis, extensive scar tissue at sites where devices are inserted)~6. Anticipated need for Magnetic resonance imaging (MRI)/Magnetic resonance angiography (MRA) during the study. Unplanned MRI/MRA requiring temporary interruption of CGM use would be allowed.~7. Use of prednisone for more than 10 days during the study.~8. Uncontrolled thyroid disease~9. Clinical diagnosis of polycystic ovarian syndrome requiring treatment.~10. Significant elevation in liver function tests (e.g. \>2-3 times normal), known infectious hepatitis or HIV.~11. History of a systemic deep tissue infection with methicillin-resistant staph aureus or Candida albicans~12. Known bleeding diathesis or dyscrasia~13. Active renal dialysis~14. Individuals with cognitive impairment that prevents understanding either consent form or intervention content~15. Psychiatric disorders that would interfere with study tasks (e.g., substance abuse)-self reported~List any restrictions on use of other drugs or treatments.~1. Acetaminophen with the use of the CGM.~2. Use of medication or intervention that significantly alters the menstrual cycle such as oral contraceptives, depoprovera, or IUD.~3. Anticipate need for MRI/MRA during the study. Unplanned MRI/MRA requiring temporary interruption of CGM use would be allowed.~4. Use of prednisone for more than 10 days during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).